NanoSyrinx raises £6.2m to develop its synthetic biology platform for targeted intracellular engineering
Coventry, United Kingdom, 19th July 2021 – NanoSyrinx, a biotech company developing a new cell engineering tool for novel targeted therapeutic modalities, has raised a further £6.2m of seed financing, co-led by incoming Octopus Ventures and existing investor M Ventures (Amsterdam, The Netherlands), the corporate venture capital arm of Merck KGaA. Previous investors BioCity and the UK Innovation & Science Seed Fund (UKI2S) joined the funding round along with experienced deeptech investor IQ Capital and Jonathan Milner. The round was significantly oversubscribed with high demand both from existing and from new investors.
Dr James Lapworth, Warwick Innovations, who has worked closely with the founding team since 2016 to develop the commercialisation strategy for the technology, said: “This latest investment into NanoSyrinx is a huge vote of confidence in the technology and in the team. It recognises not only the potential impact that nanosyringes could have as advanced medicines but also the entrepreneurial talent emerging from our researcher community.”
For commercial enquiries contact Dr James Lapworth, Warwick Innovations, email: firstname.lastname@example.org